Chargement en cours...
Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
BACKGROUND: Antiangiogenic agents that specifically target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for metastatic clear cell renal cell carcinoma (ccRCC) patients. However, most patients eventually show no responses to the ta...
Enregistré dans:
| Publié dans: | Front Genet |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8299280/ https://ncbi.nlm.nih.gov/pubmed/34306023 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fgene.2021.680369 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|